Semaglutide·Novo Nordisk·Injectable pen

Wegovy

Wegovy® is an FDA-approved once-weekly injectable semaglutide pen manufactured by Novo Nordisk, FDA-approved in June 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The FDA-approved 2.4mg maintenance dose is administered following a structured dose-escalation schedule. Weight Method does not dispense or prescribe brand-name Wegovy®. Our prescribing providers issue patient-specific prescriptions for compounded semaglutide, dispensed by U.S.-licensed 503A compounding pharmacies. Compounded semaglutide is not FDA-approved.

0.25mg0.5mg1mg1.7mg2.4mgOnce weekly
Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Wegovy is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated June 2026Medically reviewed by licensed providers

Wegovy (semaglutide) is an FDA-approved GLP-1 medication for weight loss; in trials of the brand-name product, patients lost an average of 15-22% of their body weight. Weight Method does not dispense brand-name Wegovy — it offers compounded semaglutide, prescribed by licensed providers, from $199/month with virtual consultations and direct shipping.

Key Fact

Wegovy® (semaglutide 2.4mg) is FDA-approved for chronic weight management (June 2021), manufactured by Novo Nordisk. It is administered once weekly following a 16-20 week dose-escalation schedule to the 2.4mg maintenance dose. Weight Method's compounded semaglutide program is dispensed at $154/month and is not FDA-approved.

Source: FDA approval data — Wegovy® prescribing information

How does this medication work?

Wegovy (semaglutide 2.4mg) activates GLP-1 receptors in the brain to suppress hunger, reduce cravings, and slow digestion.

Wegovy works by activating GLP-1 receptors throughout the body, primarily in the brain's appetite-regulation centers. The semaglutide in Wegovy mimics the natural GLP-1 hormone, reducing hunger signals, increasing feelings of fullness, and decreasing food cravings -- including cravings for high-fat and high-sugar foods. It also slows gastric emptying to extend satiety after meals. Wegovy is dosed to a 2.4mg maintenance level, which is higher than the diabetes-focused dosing used for Ozempic.

What is it FDA-approved for?

FDA-approved for chronic weight management (2021) and cardiovascular risk reduction (2024). The first semaglutide product with an explicit anti-obesity indication.

Wegovy is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. In March 2024, the FDA also approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight, making it the first anti-obesity medication with a cardiovascular risk reduction indication.

What are the key facts you should know?

Once-weekly injection, 2.4mg maintenance dose, 16-20 week dose escalation, manufactured by Novo Nordisk.

Wegovy is available in five dose strengths -- 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg -- following a structured 16-20 week dose-escalation schedule to the maintenance dose of 2.4mg once weekly. It is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management, and also carries an FDA-approved indication to reduce the risk of major adverse cardiovascular events in adults with cardiovascular disease and obesity or overweight.

Why choose this treatment?

Wegovy delivers the highest approved semaglutide dose, plus a distinct FDA-approved cardiovascular risk reduction indication.

Wegovy® is FDA-approved specifically for chronic weight management in adults meeting the FDA-approved indication. Patients seeking the FDA-approved brand-name Wegovy® obtain it through a retail pharmacy on a prescription from their treating provider. Weight Method does not dispense or prescribe brand-name Wegovy®. For patients who, after consultation with a Weight Method provider, choose compounded semaglutide as part of a chronic-weight-management program, Weight Method dispenses compounded semaglutide through U.S.-licensed 503A compounding pharmacies at $154/month all-inclusive (medication, licensed-provider evaluation, ongoing provider access, dose management, and home shipping). Compounded semaglutide is not FDA-approved.

Ready to Get Started?

Answer a few quick questions to see if you qualify.

Check Eligibility

Your Treatment Options

Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.

Starting at$199/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Compounded semaglutide. Once-weekly subcutaneous injection.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Compounded tirzepatide. Dual-action GLP-1/GIP, once-weekly subcutaneous injection.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Wegovy and Ozempic both contain semaglutide, but Wegovy is FDA-approved specifically for chronic weight management at a higher maximum dose (2.4mg vs. 2mg), while Ozempic is FDA-approved for type 2 diabetes. Wegovy's dosing schedule is designed to reach higher therapeutic levels. Your Weight Method provider will determine the appropriate compounded semaglutide formulation and dosing for your goals.

Wegovy is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in eligible adults. Individual outcomes vary and depend on adherence, starting weight, diet, and activity level. Your Weight Method provider will set expectations for your individualized compounded semaglutide plan during your consultation.

Yes. The SELECT trial demonstrated that Wegovy reduced the risk of major adverse cardiovascular events -- including heart attack, stroke, and cardiovascular death -- by 20% in adults with established cardiovascular disease and obesity. In March 2024, the FDA added this cardiovascular risk reduction to Wegovy's approved labeling, making it the first weight-loss medication with this indication.

Wegovy follows a gradual dose-escalation schedule over 16-20 weeks: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, then the maintenance dose of 2.4mg. This slow ramp-up minimizes gastrointestinal side effects and allows your body to adjust to the medication. Your Weight Method provider may adjust the timeline based on your tolerability.

The most common side effects are nausea, diarrhea, vomiting, constipation, and abdominal pain, primarily during dose escalation. In STEP trials, approximately 44% of participants reported nausea, though most cases were mild to moderate and resolved within weeks. Serious but rare side effects include pancreatitis, gallbladder problems, and allergic reactions. Your Weight Method provider monitors your progress to manage any side effects proactively.

No. Weight Method does not dispense or prescribe brand-name Wegovy®. Our prescribing providers issue patient-specific prescriptions for compounded semaglutide, dispensed by U.S.-licensed 503A compounding pharmacies. Weight Method's compounded semaglutide program is $154/month all-inclusive (medication, licensed-provider evaluation, ongoing provider access, dose management, and home shipping). Compounded semaglutide is not FDA-approved.

Yes, Wegovy requires a prescription from a licensed healthcare provider. At Weight Method, the process is streamlined: complete a free online quiz, receive a medical evaluation from a licensed provider, and if eligible, your prescription and medication are shipped directly to your home. No office visits or waiting rooms required.

Start Your Treatment

Speak with a licensed provider today and find out if GLP-1 medications are right for you.

Get Started Now

Free consultation. No commitment.

More about Wegovy

Wegovy Side EffectsWegovy ResultsWegovy Dosingsemaglutide Dosage Calculator

Generic Medication

Semaglutide

Other Semaglutide Brands

OzempicRybelsusOral WegovySemaglutide

Compare Wegovy

Ozempic vs WegovyWegovy vs ZepboundWegovy vs MounjaroOral Wegovy vs Wegovy

Wegovy by State

Wegovy in AlabamaWegovy in AlaskaWegovy in ArizonaWegovy in ArkansasWegovy in CaliforniaWegovy in Colorado